Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/33149

Title:	Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts
Authors:	Wiendl, H. Comi, G. Oreja-Guevara, C. Siva, A. VAN WIJMEERSCH, Bart Wuerfel, J. Buffels, R. Kadner, K. Kuenzel, T. Vermersch, P.
Issue Date:	2020
Publisher:	SAGE PUBLICATIONS LTD
Source:	Multiple Sclerosis Journal, 26 (3_SUPPL) , p. 224 -225
Document URI:	http://hdl.handle.net/1942/33149
ISSN:	1352-4585
e-ISSN:	1477-0970
ISI #:	WOS:000596547100445
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

1

checked on May 2, 2024

32

checked on Jul 28, 2023

Check